FDA sets new date for panel review of Sarepta's muscle drug

(Reuters) - An independent panel of experts to the U.S. Food and Drug Administration (FDA) will discuss Sarepta Therapeutics Inc's muscle wasting drug on April 25, nearly three months after the original date. The agency on Jan. 20 postponed the meeting evaluating the company's keenly watched Duchenne muscular dystrophy drug, eteplirsen, due to an inclement weather forecast for Washington DC. There are no FDA-approved drugs for DMD, and pressure has been mounting on the agency to swiftly approve treatments.